CA2536047A1 - Spray-dried amorphous bibn 4096 method for production and use thereof as inhalant - Google Patents
Spray-dried amorphous bibn 4096 method for production and use thereof as inhalant Download PDFInfo
- Publication number
- CA2536047A1 CA2536047A1 CA002536047A CA2536047A CA2536047A1 CA 2536047 A1 CA2536047 A1 CA 2536047A1 CA 002536047 A CA002536047 A CA 002536047A CA 2536047 A CA2536047 A CA 2536047A CA 2536047 A1 CA2536047 A1 CA 2536047A1
- Authority
- CA
- Canada
- Prior art keywords
- active substance
- drying gas
- particularly preferably
- microparticles
- drying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the CGRP antagonist 1-[N?2¿-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A), or the physiologically-acceptable salts thereof, which are stable in the amorphous state under normal conditions (T < 50 ·C, relative humidity < 75%) in the form of microparticles, methods for production of microparticles of said substances and the use of said microparticles for the production of a medicament in the application form of a powder inhalant for pulmonary and nasal inhalation, in particular, for the production of a medicament for the treatment of headaches, migraines and cluster headaches.
Description
Boehringer Ingelheim International GmbH Case 1/1547 55216 Ingelheim foreign filing text 84772fft Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative s The invention relates to the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(11~-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) and the physiologically acceptable salts thereof which are stable in the amorphous state under normal conditions (T < 50°C, relative humidity <
75%) and are in the form of microparticles, processes for preparing such microparticles from ~o these substances and the use of these particles for preparing a pharmaceutical composition of the inhalable powder type for pulmonary and nasal inhalation, particularly for preparing a pharmaceutical composition for the treatment of headaches, migraine and cluster headache.
15 Background to the invention The CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(11-~-oxoquinazolin-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) is known from International Patent Application PCT/EP97/04862 (published as WO
98/11128) and has the following structure:
Br OH
w ~Br O
\ N'~N ~ N
N
N" O H O
(A) Prior art The active substance base (A) is a highly effective CGRP antagonist for the acute 2s and prophylactic treatment of headaches, particularly migraine and cluster headache, which cannot be administered orally using conventional formulations, as the substance has very limited oral bioavailability.
- 2 - Case 1/1547 foreign filing text For treating attacks of migraine it is essential that an active substance is systemically available as quickly as possible. The treatment should be uncomplicated for the patient to administer and no other conditions which could affect bioavailability (e.g.
the food effect) should restrict the use of the medicament for the patient.
Active substances which are intended to be systemically available are usually administered by oral route. If this route is unsuitable or undesirable on account of particular properties of the active substance or particular demands made of the 1o application, other possible ways of administering substances systemically are known in the art. For example, inhalation, by means of which active substances may be administered systemically as well as topically, has been under discussion for some time. For substances which prove critical on account of their decomposition in solution or which have poor solubility per se, powder inhalation is an option.
The absolute amount of the active substance which has to be administered per application makes particular demands of the formulation. On the other hand, the physical stability (e.g. aerodynamic particle size, dispersibility, physicochemical properties) of the active substance has proved to be a critical requirement for the development and production of an inhalable powder.
With formulations of the powder inhalant type, inhalable powders, which are packaged for example in suitable capsules (inhalettes), are delivered to the lungs by means of powder inhalers. Similarly, other systems in which the quantity of powder to be administered is pre-dosed (e.g. blisters),are also known as multidose powder systems. Alternatively, the medicament may also be inhaled by the use of suitable powdered inhalable aerosols which are suspended for example in HFA134a, HFA227 or mixtures thereof as propellant gas.
In powder inhalation, the microparticles of a pure active substance are administered so through the airways onto the surface of the lungs, e.g. in the alveoli, by the inhalation process. These particles settle on the surtace and can only be absorbed into the body after the dissolving process by active and passive transporting processes.
- 3 - Case 1/1547 foreign filing text Inhalation systems are known in the literature in which the active substance is present in the form of solid particles either as a micronised suspension in a suitable solvent system as carrier or in the form of a dry powder.
Usually, powder inhalants, e.g. in the form of capsules for inhalation, are prepared on s the basis of the general teaching as described in DE-A-179 22 07.
A critical factor in multi-substance systems of this kind is the uniform distribution of the pharmaceutical composition in the powder mixture.
The pharmaceutical active substance used to prepare the above-mentioned pharmaceutical composition should be as pure as possible and its stability on long-~o term storage must be guaranteed under different environmental conditions.
This is absolutely essential in order to prevent the use of pharmaceutical compositions in which breakdown products, for example, are present together with the active substance itself.
15 Apart from the requirements concerning chemical stability of the active substance s outlined above it must be generally borne in mind that any change to the solid state of a pharmaceutical composition or to the active substance used which improves its physical and chemical stability gives a considerable advantage over less stable forms of the same pharmaceutical composition. Different physical / physicochemical 2o properties may, however, bring about improved pharmacological /
pharmacokinetic properties of the pharmaceutical composition in some cases. In particular, depending on the formulation, special morphological properties of solid particles may be beneficial to the preparation of a pharmaceutical composition.
25 It is known from the literature that particles in the submicron range can be produced by spray-drying. Usually, industrially suitable formulations which exhibit sufficient dispersibility in medical use (inhalation) may be prepared from spray-dried particles of this kind in accordance with the method cited above (DE-A-179 22 07) [Y.-F.
Maa, P.-A. Ngyuyen, J.D. Andya, N. Dasovich, T.D. Sweeny, S.J. Shire, C.C. Hsu, so Pharmaceutical Research, 15, No. 5 (1998), 768-775; M.T. Vidgren, P.A.
Vidgr~n, T.P. Paronen, Int. J. Pharmaceutics, 35 (1987), 139-144; R.W. Niven, F.D.
Lott, A.Y.
Ip, J.M. Cribbs, Pharmaceutical Research, 11, No. 8 (1994), 1101-1109].
75%) and are in the form of microparticles, processes for preparing such microparticles from ~o these substances and the use of these particles for preparing a pharmaceutical composition of the inhalable powder type for pulmonary and nasal inhalation, particularly for preparing a pharmaceutical composition for the treatment of headaches, migraine and cluster headache.
15 Background to the invention The CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(11-~-oxoquinazolin-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) is known from International Patent Application PCT/EP97/04862 (published as WO
98/11128) and has the following structure:
Br OH
w ~Br O
\ N'~N ~ N
N
N" O H O
(A) Prior art The active substance base (A) is a highly effective CGRP antagonist for the acute 2s and prophylactic treatment of headaches, particularly migraine and cluster headache, which cannot be administered orally using conventional formulations, as the substance has very limited oral bioavailability.
- 2 - Case 1/1547 foreign filing text For treating attacks of migraine it is essential that an active substance is systemically available as quickly as possible. The treatment should be uncomplicated for the patient to administer and no other conditions which could affect bioavailability (e.g.
the food effect) should restrict the use of the medicament for the patient.
Active substances which are intended to be systemically available are usually administered by oral route. If this route is unsuitable or undesirable on account of particular properties of the active substance or particular demands made of the 1o application, other possible ways of administering substances systemically are known in the art. For example, inhalation, by means of which active substances may be administered systemically as well as topically, has been under discussion for some time. For substances which prove critical on account of their decomposition in solution or which have poor solubility per se, powder inhalation is an option.
The absolute amount of the active substance which has to be administered per application makes particular demands of the formulation. On the other hand, the physical stability (e.g. aerodynamic particle size, dispersibility, physicochemical properties) of the active substance has proved to be a critical requirement for the development and production of an inhalable powder.
With formulations of the powder inhalant type, inhalable powders, which are packaged for example in suitable capsules (inhalettes), are delivered to the lungs by means of powder inhalers. Similarly, other systems in which the quantity of powder to be administered is pre-dosed (e.g. blisters),are also known as multidose powder systems. Alternatively, the medicament may also be inhaled by the use of suitable powdered inhalable aerosols which are suspended for example in HFA134a, HFA227 or mixtures thereof as propellant gas.
In powder inhalation, the microparticles of a pure active substance are administered so through the airways onto the surface of the lungs, e.g. in the alveoli, by the inhalation process. These particles settle on the surtace and can only be absorbed into the body after the dissolving process by active and passive transporting processes.
- 3 - Case 1/1547 foreign filing text Inhalation systems are known in the literature in which the active substance is present in the form of solid particles either as a micronised suspension in a suitable solvent system as carrier or in the form of a dry powder.
Usually, powder inhalants, e.g. in the form of capsules for inhalation, are prepared on s the basis of the general teaching as described in DE-A-179 22 07.
A critical factor in multi-substance systems of this kind is the uniform distribution of the pharmaceutical composition in the powder mixture.
The pharmaceutical active substance used to prepare the above-mentioned pharmaceutical composition should be as pure as possible and its stability on long-~o term storage must be guaranteed under different environmental conditions.
This is absolutely essential in order to prevent the use of pharmaceutical compositions in which breakdown products, for example, are present together with the active substance itself.
15 Apart from the requirements concerning chemical stability of the active substance s outlined above it must be generally borne in mind that any change to the solid state of a pharmaceutical composition or to the active substance used which improves its physical and chemical stability gives a considerable advantage over less stable forms of the same pharmaceutical composition. Different physical / physicochemical 2o properties may, however, bring about improved pharmacological /
pharmacokinetic properties of the pharmaceutical composition in some cases. In particular, depending on the formulation, special morphological properties of solid particles may be beneficial to the preparation of a pharmaceutical composition.
25 It is known from the literature that particles in the submicron range can be produced by spray-drying. Usually, industrially suitable formulations which exhibit sufficient dispersibility in medical use (inhalation) may be prepared from spray-dried particles of this kind in accordance with the method cited above (DE-A-179 22 07) [Y.-F.
Maa, P.-A. Ngyuyen, J.D. Andya, N. Dasovich, T.D. Sweeny, S.J. Shire, C.C. Hsu, so Pharmaceutical Research, 15, No. 5 (1998), 768-775; M.T. Vidgren, P.A.
Vidgr~n, T.P. Paronen, Int. J. Pharmaceutics, 35 (1987), 139-144; R.W. Niven, F.D.
Lott, A.Y.
Ip, J.M. Cribbs, Pharmaceutical Research, 11, No. 8 (1994), 1101-1109].
- 4 - Case 1/1547 foreign filing text It is also known from the literature that using special methods it is possible to produce so-called "large porous particles" which have proved particularly suitable for use in powder inhalants (D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A.
Ben-Jebria, M. L. Eskew, J. Mintzes, D. Deaver, N. Lotan, R. Langer, Science, 276 (1997) 1868-1871 ). By these are meant particles with a mean geometric size of more than 5 Nm (e.g. 8.5 pm to 20 pm), which behave aerodynamically in the same way as particles less than 5 pm in size, these powders also being characterised by an extremely low density (< 0.4 g/cm3).
1o Statement of the problem The complex problem of the present invention was thus primarily to provide novel stable microparticles of the active substance base 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(11-~-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) and the physiologically acceptable salts thereof, which meet the stringent requirements mentioned above that are imposed on a pharmaceutical active substance for a powder inhalant for pulmonary and nasal inhalation and compared with conventional micronised starting material (obtained e.g. by air-jet grinding) have proved suitable for use as powder inhalants in terms of their pharmacological / pharmacokinetic properties. According to the invention the 2o morphology of the microparticles was to be optimised so that the formulation consisting thereof preferably contains no excipient and hence consists exclusively of active substance.
The formulation according to the invention should also exhibit a rapid onset of activity 2s for the treatment of the acute pain which occurs very suddenly in the case of migraine. This means that rapid absorption of the active substance and a rapid increase in the plasma level must be guaranteed.
Detailed description of the invention so A rapid onset of activity for the treatment of acute pain as well as a high plasma level of the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1l-~-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) and the physiologically acceptable salts thereof within a very short time can best be achieved through the lungs as the site of absorption.
Ben-Jebria, M. L. Eskew, J. Mintzes, D. Deaver, N. Lotan, R. Langer, Science, 276 (1997) 1868-1871 ). By these are meant particles with a mean geometric size of more than 5 Nm (e.g. 8.5 pm to 20 pm), which behave aerodynamically in the same way as particles less than 5 pm in size, these powders also being characterised by an extremely low density (< 0.4 g/cm3).
1o Statement of the problem The complex problem of the present invention was thus primarily to provide novel stable microparticles of the active substance base 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(11-~-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) and the physiologically acceptable salts thereof, which meet the stringent requirements mentioned above that are imposed on a pharmaceutical active substance for a powder inhalant for pulmonary and nasal inhalation and compared with conventional micronised starting material (obtained e.g. by air-jet grinding) have proved suitable for use as powder inhalants in terms of their pharmacological / pharmacokinetic properties. According to the invention the 2o morphology of the microparticles was to be optimised so that the formulation consisting thereof preferably contains no excipient and hence consists exclusively of active substance.
The formulation according to the invention should also exhibit a rapid onset of activity 2s for the treatment of the acute pain which occurs very suddenly in the case of migraine. This means that rapid absorption of the active substance and a rapid increase in the plasma level must be guaranteed.
Detailed description of the invention so A rapid onset of activity for the treatment of acute pain as well as a high plasma level of the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1l-~-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) and the physiologically acceptable salts thereof within a very short time can best be achieved through the lungs as the site of absorption.
- 5 - Case 1/1547 foreign filing text It has been found that when the active substance (A) is administered by inhalation in the form of a powder inhalant a bioavailability of about 60% can be achieved based on the fine content of the formulation (corresponding to FPD "fine particle dose"', determined according to USP 24 Suppl. 2000).
The present invention therefore consists in the preparation of novel, stable microparticles of the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(11~-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) and the physiologically acceptable salts thereof, which are surprisingly 1o especially suitable for preparing powder inhalants for pulmonary and nasal inhalation.
They are characterised by special physical and physicochemical properties, which lead to an improved pharmacological as well as pharmacokinetic activity when the substance is inhaled. One surprising feature is that by varying/optimising the particle shape of these particles with a large specific surface area, the aerodynamic 15 properties and also the increase in dispersibility and inhalability can be improved.
The invention also includes the chief method of preparing microparticles of this kind and the use thereof for preparing pharmaceutical compositions in the form of a powder inhalant.
2o According to the invention in addition to the active substance base the corresponding physiologically acceptable acid addition salts are used which are selected for example from among 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(11-IJ-oxoquinazolin-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine hydrochloride, sulphate, phosphate, hydrobromide, carbonate, methanesulphonate, p-25 toluenesulphonate, nitrate, citrate, malate, tartrate, lactate, succinate, gluconate, acetate, formate, propionate, capronate, oxalate, maleate, fumarate, mandelate and hydroxysuccinate, while the 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(11~-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine hydrochloride, the sulphate and the hydrobromide are preferred and the 30 1-[NZ-[3, 5-d i bromo-N-[[4-(3,4-d i hyd ro-2( 11-x-oxoq a i nazoli n-3-yl)-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine hydrochloride as well as the free active substance base are particularly preferred.
The present invention therefore consists in the preparation of novel, stable microparticles of the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(11~-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) and the physiologically acceptable salts thereof, which are surprisingly 1o especially suitable for preparing powder inhalants for pulmonary and nasal inhalation.
They are characterised by special physical and physicochemical properties, which lead to an improved pharmacological as well as pharmacokinetic activity when the substance is inhaled. One surprising feature is that by varying/optimising the particle shape of these particles with a large specific surface area, the aerodynamic 15 properties and also the increase in dispersibility and inhalability can be improved.
The invention also includes the chief method of preparing microparticles of this kind and the use thereof for preparing pharmaceutical compositions in the form of a powder inhalant.
2o According to the invention in addition to the active substance base the corresponding physiologically acceptable acid addition salts are used which are selected for example from among 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(11-IJ-oxoquinazolin-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine hydrochloride, sulphate, phosphate, hydrobromide, carbonate, methanesulphonate, p-25 toluenesulphonate, nitrate, citrate, malate, tartrate, lactate, succinate, gluconate, acetate, formate, propionate, capronate, oxalate, maleate, fumarate, mandelate and hydroxysuccinate, while the 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(11~-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine hydrochloride, the sulphate and the hydrobromide are preferred and the 30 1-[NZ-[3, 5-d i bromo-N-[[4-(3,4-d i hyd ro-2( 11-x-oxoq a i nazoli n-3-yl)-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine hydrochloride as well as the free active substance base are particularly preferred.
- 6 - Case 1/1547 foreign filing text Particle geometries of the microparticles which have proved advantageous may be described as collapsed hemispheres and have a crinkled structure. In terms of geometry, particles prepared by the processes described below have particle shapes which may be described, depending on the test conditions, between the extremes of "spherical shell fragment", "thin-walled, totally collapsed sphere ", "crinkled, filigree-flaked platelet structure", as well as "rosette-like crinkled structure".
These particles are characterised in that (a) they have a specific surface area between 3 mz/g and 35 m2/g, preferably between 5 m2/g and 30 m2/g and particularly preferably between 10 m2/g and 30 m2/g, (b) the characteristic Q~S.a~ is between 50% and 100% and (c) the parameter X5o is in the range from 0.5 Nm to 10 Nm, preferably from 0.5 Nm to 6 Nm.
The crinkled microparticles according to the invention are suitable for preparing 2o powder inhalants for pulmonary and nasal inhalation, in which no other excipients or additives (carrier materials) are needed in order to obtain an industrially workable powder which can be further processed directly and which has excellent properties in terms of dispersibility and is sufficiently easy to process with regard to its cohesive properties.
In a first aspect the present invention thus relates to a powder inhalant for pulmonary and nasal inhalation, comprising the CGRP antagonist 1-[NZ-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1 f-~-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) or one of the physiologically acceptable salts thereof in the so form of crinkled microparticles, characterised in that (a) they have a specific surface area between 3 m2/g and 35 m2/g, preferably between 5 m2/g and 30 mZ/g and particularly preferably between 10 m2/g and m2/g, 7 - Case 1 /1547 foreign filing text (b) the characteristic Q~S.s> is between 50% and 100% and (c) the parameter X5o is in the range from 0.5 Nm to 10 Nm, preferably from 0.5 s pm to 6 Nm.
The crinkled microparticles according to the invention are however also suitable for preparing powder inhalants wherein the active substance is administered together with an excipient.
Normal carrier materials or flow adjuvants may be used as physiologically acceptable homogeneous excipients according to the invention. The normal carrier materials may be selected from among the monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose, trehalose), oligo- and polysaccharides (e.g. dextrans, starch, cellulose derivatives), polyalcohols (e.g.
mannitol, sorbitol, xylitol), salts (e.g. sodium chloride, calcium carbonate), polylactides, polyglycolides and mixtures of these excipients. The flow adjuvants may for example be selected from a group consisting of magnesium stearate, calcium stearate, stearic acid, stearyl alcohols, calcium behenate, calcium arachinate, 2o hydrogenated vegetable oils such as for example hydrogenated castor oil or hydrogenated cottonseed oil, fatty acid esters, sodium stearyl fumarate, sodium dodecyl sulphate, magnesium dodecyl sulphate and mixtures of these flow adjuvants.
The method of preparing the microparticles according to the invention is 2s characterised in that the active substance is suitably dissolved, sprayed and dried in a spraying tower. The particle morphology including the particle size of these microparticles can be deliberately controlled by the choice of process parameters and production parameters.
ao In a second aspect the present invention thus relates to a process for producing the microparticles of the active substance base (A) according to the invention, comprising the following steps:
- $ - Case 1/1547 foreign filing text (a) dissolving the active substance (A) in an organic solvent or an organic-aqueous solvent mixture to prepare a sprayable solution with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.%
and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way, so as to obtain a spray mist with a droplet size having the characteristic X5o from 1 to 50 Nm, preferably from 1 Nm to 30 pm, particularly preferably from 1 Nm to 20 Nm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C
and (ii) an exit temperature of the drying gas from 40°C to 120°C
and (d) separating the dried solid fraction from the current of drying gas in the usual way.
Preferably the microparticles of the active substance base (A) according to the invention are prepared by a method comprising the following steps:
(a) dissolving the active substance (A) in an organic solvent or an organic aqueous solvent mixture in order to prepare a sprayable solution with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way with a flow volume of spray gas of from 1 Nm3/h to 15 Nm3/h, so as to obtain a spray - g - Case 1 /1547 foreign filing text mist with a droplet size having the characteristic X5o from 1 to 50 pm, preferably from 1 Nm to 30 Nm, particularly preferably from 1 pm to 20 Nm, (c) drying the spray mist thus obtained using a drying gas while applying the s following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C, (ii) an exit temperature of the drying gas from 40°C to 120°C
and (iii) a flow volume of the drying gas from 15 Nm3/h to 150 Nm3/h and (d) separating the dried solid fraction from the current of drying gas in the usual 1 s way.
Organic solvents, organic-aqueous solvent mixtures and water have proved suitable as solvents for preparing a sprayable solution of the active substance base.
Preferably an alcoholic or alcoholic-aqueous solvent system is used, particularly 2o preferably a solvent mixture consisting of ethanol/methanol/water or ethanol/propanol/water and most particularly preferably the solvent mixture of ethanol/water or the solvent absolute ethanol, methanol or water.
In a third aspect the present invention relates to a process for preparing the 25 microparticles of the salts of the active substance base (A) according to the invention, comprising the following steps:
(a) dissolving the active substance base (A) in water or an aqueous buffer system and adding the corresponding acid in order to prepare a sprayable salt ao solution of the active substance with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, - 10 - Case 1 /1547 foreign filing text (b) spraying the active substance solution thus obtained in the usual way, so as to obtain a spray mist with a droplet size having the characteristic X5o from 1 to 50 Nm, preferably from 1 Nm to 30 Nm, particularly preferably from 1 Nm to 20 Nm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably 1o from 120°C to 250°C and particularly preferably from 130°C to 200°C
and (ii) an exit temperature of the drying gas from 40°C to 120°C
and (d) separating the dried solid fraction from the current of drying gas in the usual way.
Preferably the microparticles of the salts of the active substance base (A) according 2o to the invention are prepared by a method comprising the following steps:
(a) dissolving the active substance base (A) in water or an aqueous buffer system and adding the corresponding acid in order to prepare a sprayable salt solution of the active substance with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way with a flow volume of spray gas of from 1 Nm3/h to 15 Nm3/h, so as to obtain a spray so mist with a droplet size having the characteristic X5o from 1 to 50 Nm, preferably from 1 Nm to 30 Nm, particularly preferably from 1 Nm to 20 Nm, while applying the following parameters:
- 11 - Case 1/1547 foreign filing text (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C, (ii) an exit temperature of the drying gas from 40°C to 120°C
and (iii) a flow volume of the drying gas from 15 Nm3/h to 150 Nm3/h and (d) separating the dried solid fraction from the current of drying gas in the usual way.
Water or an aqueous buffer system with a pH between 6 and 8 have proved suitable 1s as solvents for preparing a sprayable solution of the salt forms of the active substance base (A). The active substance according to the invention which is present in the form of the free base is dissolved in an aqueous solution, which is combined with 0.9 to 1.1 equivalents of acid, according to the quantity of active substance to be dissolved, in the form of the corresponding salt. The acids according to the invention 2o are preferably inorganic acids (for example hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulphuric acid, carbonic acid), fruit acids (for example citric acid, malic acid, tartaric acid, lactic acid, succinic acid, gluconic acid), carboxylic acids (for example formic acid, acetic acid, propionic acid, hexanoic acid) as well as other organic acids such as oxalic acid, methanesulphonic acid, p-toluenesulphonic 25 acid, fumaric acid, mandelic acid or malefic acid; it is particularly preferable to use hydrochloric acid, hydrobromic acid or sulphuric acid and particularly hydrochloric acid.
The surface qualities of the particles can be optimised by adjusting the ratio between so the droplet size and solids concentration. Normally a concentration of between 0.2 and 4 wt.%, preferably between 0.2 and 3 wt.%, most preferably between 0.3 and wt.% is selected.
- 12 - Case 1 /1547 foreign filing text The droplet size is a crucial parameter in the production of inhalable particles.
Depending on the nozzle used the throughput of spray gas combined with the throughput of solution should be selected to achieve the desired droplet size.
As there are a number of combinations of the parameters nozzle / throughput of spray gas / throughput of solution leading to a suitable droplet size, the process can usefully be defined by the droplet size which is obtained with the same nozzle parameters with water at ambient temperature. These may be described by the characteristic X5o (median value of droplet size below which 50°/a by volume of the droplet fraction falls), which should be in the range from 1 Nm to 50 pm.
The critical characteristics which impinge on the drying step are the entry and exit temperature of the drying gas, as well as the flow volume of the drying gas passing through.
In a fourth aspect the present invention relates to the use of the crinkled microparticles produced by the processes described hereinbefore for the production of a powder inhalant.
In a fifth aspect the present invention relates to the microparticles according to the 2o invention, which can be obtained according to the processes described above.
- 13 - Case 1/1547 foreign filing text Experimental section 1) Methods of measurement s a) Determining the particle size by laser diffraction (Frauenhofer diffraction):
Measuring method: In order to determine the particle size the powder is fed into a laser diffraction spectrometer using a dispersing unit.
The median value X5o refers to the particle size below which to 50% of the quantity of particles fall. The Q~s.a~ value describes the percentage of particles which are less than 5.8 Nm in size.
Measuring device: Laser diffraction spectrometer (HELOS), Messrs. Sympatec Software: WINDOX 4 15 Dispersing unit: RODOS / dispersing pressure: 3 bar Focal length: 100 mm [measuring range: 0.9.....175 pm]
Evaluation method: HRLD (V 4) b) Determining the Specific Surface Area:
Measuring method: The specific surface is determined by exposing the powder sample to a nitrogen atmosphere at different pressures. Cooling the sample causes the nitrogen molecules to be condensed on the surface of the particles. The quantity of condensed nitrogen 2s is determined by means of the drop in pressure in the system and the surface of the sample is calculated by means of the surface nitrogen requirement and the weight of the sample.
so Measuring device: Tri Star Multi Point BET, Messrs. Micromeritics Heating station: VacPrep 061, Messrs. Micromeritics Heating: approx. 12 h / 40 °C
- 14 - Case 1 /1547 foreign filing text Analysis parameters sample tube: 'h inch; with filler rod analysis method: 16 point BET surface measurement 0.05 to 0.20 p/p0 absolute pressure tolerance: 5.0 mm Hg relative pressure tolerance: 5.0%
evacuation rate: 50.0 mm Hg/second evacuation threshold: 10.0 mm Hg evacuation time: 0.1 h 1 o free space: lower Dewar, t: 0.5 h retention time: 20 seconds minimum equilibration delay: 600 seconds adsorptive: nitrogen C) Determining the droplet size by laser diffraction (according to Mie):
Measuring device: Laser diffraction spectrometer (HELOS), Messrs. Sympatec Software: WINDOX 4 Focal length: 100 mm [measuring range: 0.9.....175 Nm]
2o Measuring method: The droplet size is determined by removing the nozzle from the spray dryer and placing the spray in the upper third of the spray cone in the centre of the laser beam.
Measuring is done at ambient temperature with water as reference medium under otherwise identical conditions.
- 15 - Case 1 /1547 foreign filing text 2) Examples of spray parameters Exa J~le: Spray parameters suitable for an alcoholic solution of (A) (NIRO
Spray dryer SD Micro):
Concentration solution 0.5 g (A) in 100 mL ethanol Droplet size X5o 11 Nm (Reference solution: Hz0 at ambient tem erature Flow volume "spray rate" 4.5 mL / min Spray pressure 0.7 bar overpressure (N2) (nozzle type) (Niro spray nozzle 0.5 mm, Art.-Nr. 248709/A) Flow volume "Atomising pressure"2.2 kg / h (nozzle type) (Niro spray nozzle 0.5 mm, Art.-Nr. 248709/A) entry temperature 149C
exit temperature 96C
Flow volume of "drying gas" 20.1 kg / h cross section of drying tower200 mm 3) Characterisation of the solid particles obtained in the above Example:
~ o Example:
Particle size X5o ~ 1.2 ~m Q~s.s> ~ 99.5%
Specific surface area Sm 21.5 mz/g - 16 - Case 1 /1547 foreign filing text Brief description of the Figures Figures 1 and 2 show photographs of microparticles of the active substance base (A), prepared from an alcoholic spray solution by the process according to the invention.
These particles are characterised in that (a) they have a specific surface area between 3 mz/g and 35 m2/g, preferably between 5 m2/g and 30 m2/g and particularly preferably between 10 m2/g and 30 m2/g, (b) the characteristic Q~S.a~ is between 50% and 100% and (c) the parameter X5o is in the range from 0.5 Nm to 10 Nm, preferably from 0.5 Nm to 6 Nm.
The crinkled microparticles according to the invention are suitable for preparing 2o powder inhalants for pulmonary and nasal inhalation, in which no other excipients or additives (carrier materials) are needed in order to obtain an industrially workable powder which can be further processed directly and which has excellent properties in terms of dispersibility and is sufficiently easy to process with regard to its cohesive properties.
In a first aspect the present invention thus relates to a powder inhalant for pulmonary and nasal inhalation, comprising the CGRP antagonist 1-[NZ-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1 f-~-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) or one of the physiologically acceptable salts thereof in the so form of crinkled microparticles, characterised in that (a) they have a specific surface area between 3 m2/g and 35 m2/g, preferably between 5 m2/g and 30 mZ/g and particularly preferably between 10 m2/g and m2/g, 7 - Case 1 /1547 foreign filing text (b) the characteristic Q~S.s> is between 50% and 100% and (c) the parameter X5o is in the range from 0.5 Nm to 10 Nm, preferably from 0.5 s pm to 6 Nm.
The crinkled microparticles according to the invention are however also suitable for preparing powder inhalants wherein the active substance is administered together with an excipient.
Normal carrier materials or flow adjuvants may be used as physiologically acceptable homogeneous excipients according to the invention. The normal carrier materials may be selected from among the monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose, trehalose), oligo- and polysaccharides (e.g. dextrans, starch, cellulose derivatives), polyalcohols (e.g.
mannitol, sorbitol, xylitol), salts (e.g. sodium chloride, calcium carbonate), polylactides, polyglycolides and mixtures of these excipients. The flow adjuvants may for example be selected from a group consisting of magnesium stearate, calcium stearate, stearic acid, stearyl alcohols, calcium behenate, calcium arachinate, 2o hydrogenated vegetable oils such as for example hydrogenated castor oil or hydrogenated cottonseed oil, fatty acid esters, sodium stearyl fumarate, sodium dodecyl sulphate, magnesium dodecyl sulphate and mixtures of these flow adjuvants.
The method of preparing the microparticles according to the invention is 2s characterised in that the active substance is suitably dissolved, sprayed and dried in a spraying tower. The particle morphology including the particle size of these microparticles can be deliberately controlled by the choice of process parameters and production parameters.
ao In a second aspect the present invention thus relates to a process for producing the microparticles of the active substance base (A) according to the invention, comprising the following steps:
- $ - Case 1/1547 foreign filing text (a) dissolving the active substance (A) in an organic solvent or an organic-aqueous solvent mixture to prepare a sprayable solution with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.%
and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way, so as to obtain a spray mist with a droplet size having the characteristic X5o from 1 to 50 Nm, preferably from 1 Nm to 30 pm, particularly preferably from 1 Nm to 20 Nm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C
and (ii) an exit temperature of the drying gas from 40°C to 120°C
and (d) separating the dried solid fraction from the current of drying gas in the usual way.
Preferably the microparticles of the active substance base (A) according to the invention are prepared by a method comprising the following steps:
(a) dissolving the active substance (A) in an organic solvent or an organic aqueous solvent mixture in order to prepare a sprayable solution with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way with a flow volume of spray gas of from 1 Nm3/h to 15 Nm3/h, so as to obtain a spray - g - Case 1 /1547 foreign filing text mist with a droplet size having the characteristic X5o from 1 to 50 pm, preferably from 1 Nm to 30 Nm, particularly preferably from 1 pm to 20 Nm, (c) drying the spray mist thus obtained using a drying gas while applying the s following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C, (ii) an exit temperature of the drying gas from 40°C to 120°C
and (iii) a flow volume of the drying gas from 15 Nm3/h to 150 Nm3/h and (d) separating the dried solid fraction from the current of drying gas in the usual 1 s way.
Organic solvents, organic-aqueous solvent mixtures and water have proved suitable as solvents for preparing a sprayable solution of the active substance base.
Preferably an alcoholic or alcoholic-aqueous solvent system is used, particularly 2o preferably a solvent mixture consisting of ethanol/methanol/water or ethanol/propanol/water and most particularly preferably the solvent mixture of ethanol/water or the solvent absolute ethanol, methanol or water.
In a third aspect the present invention relates to a process for preparing the 25 microparticles of the salts of the active substance base (A) according to the invention, comprising the following steps:
(a) dissolving the active substance base (A) in water or an aqueous buffer system and adding the corresponding acid in order to prepare a sprayable salt ao solution of the active substance with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, - 10 - Case 1 /1547 foreign filing text (b) spraying the active substance solution thus obtained in the usual way, so as to obtain a spray mist with a droplet size having the characteristic X5o from 1 to 50 Nm, preferably from 1 Nm to 30 Nm, particularly preferably from 1 Nm to 20 Nm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably 1o from 120°C to 250°C and particularly preferably from 130°C to 200°C
and (ii) an exit temperature of the drying gas from 40°C to 120°C
and (d) separating the dried solid fraction from the current of drying gas in the usual way.
Preferably the microparticles of the salts of the active substance base (A) according 2o to the invention are prepared by a method comprising the following steps:
(a) dissolving the active substance base (A) in water or an aqueous buffer system and adding the corresponding acid in order to prepare a sprayable salt solution of the active substance with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way with a flow volume of spray gas of from 1 Nm3/h to 15 Nm3/h, so as to obtain a spray so mist with a droplet size having the characteristic X5o from 1 to 50 Nm, preferably from 1 Nm to 30 Nm, particularly preferably from 1 Nm to 20 Nm, while applying the following parameters:
- 11 - Case 1/1547 foreign filing text (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C, (ii) an exit temperature of the drying gas from 40°C to 120°C
and (iii) a flow volume of the drying gas from 15 Nm3/h to 150 Nm3/h and (d) separating the dried solid fraction from the current of drying gas in the usual way.
Water or an aqueous buffer system with a pH between 6 and 8 have proved suitable 1s as solvents for preparing a sprayable solution of the salt forms of the active substance base (A). The active substance according to the invention which is present in the form of the free base is dissolved in an aqueous solution, which is combined with 0.9 to 1.1 equivalents of acid, according to the quantity of active substance to be dissolved, in the form of the corresponding salt. The acids according to the invention 2o are preferably inorganic acids (for example hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulphuric acid, carbonic acid), fruit acids (for example citric acid, malic acid, tartaric acid, lactic acid, succinic acid, gluconic acid), carboxylic acids (for example formic acid, acetic acid, propionic acid, hexanoic acid) as well as other organic acids such as oxalic acid, methanesulphonic acid, p-toluenesulphonic 25 acid, fumaric acid, mandelic acid or malefic acid; it is particularly preferable to use hydrochloric acid, hydrobromic acid or sulphuric acid and particularly hydrochloric acid.
The surface qualities of the particles can be optimised by adjusting the ratio between so the droplet size and solids concentration. Normally a concentration of between 0.2 and 4 wt.%, preferably between 0.2 and 3 wt.%, most preferably between 0.3 and wt.% is selected.
- 12 - Case 1 /1547 foreign filing text The droplet size is a crucial parameter in the production of inhalable particles.
Depending on the nozzle used the throughput of spray gas combined with the throughput of solution should be selected to achieve the desired droplet size.
As there are a number of combinations of the parameters nozzle / throughput of spray gas / throughput of solution leading to a suitable droplet size, the process can usefully be defined by the droplet size which is obtained with the same nozzle parameters with water at ambient temperature. These may be described by the characteristic X5o (median value of droplet size below which 50°/a by volume of the droplet fraction falls), which should be in the range from 1 Nm to 50 pm.
The critical characteristics which impinge on the drying step are the entry and exit temperature of the drying gas, as well as the flow volume of the drying gas passing through.
In a fourth aspect the present invention relates to the use of the crinkled microparticles produced by the processes described hereinbefore for the production of a powder inhalant.
In a fifth aspect the present invention relates to the microparticles according to the 2o invention, which can be obtained according to the processes described above.
- 13 - Case 1/1547 foreign filing text Experimental section 1) Methods of measurement s a) Determining the particle size by laser diffraction (Frauenhofer diffraction):
Measuring method: In order to determine the particle size the powder is fed into a laser diffraction spectrometer using a dispersing unit.
The median value X5o refers to the particle size below which to 50% of the quantity of particles fall. The Q~s.a~ value describes the percentage of particles which are less than 5.8 Nm in size.
Measuring device: Laser diffraction spectrometer (HELOS), Messrs. Sympatec Software: WINDOX 4 15 Dispersing unit: RODOS / dispersing pressure: 3 bar Focal length: 100 mm [measuring range: 0.9.....175 pm]
Evaluation method: HRLD (V 4) b) Determining the Specific Surface Area:
Measuring method: The specific surface is determined by exposing the powder sample to a nitrogen atmosphere at different pressures. Cooling the sample causes the nitrogen molecules to be condensed on the surface of the particles. The quantity of condensed nitrogen 2s is determined by means of the drop in pressure in the system and the surface of the sample is calculated by means of the surface nitrogen requirement and the weight of the sample.
so Measuring device: Tri Star Multi Point BET, Messrs. Micromeritics Heating station: VacPrep 061, Messrs. Micromeritics Heating: approx. 12 h / 40 °C
- 14 - Case 1 /1547 foreign filing text Analysis parameters sample tube: 'h inch; with filler rod analysis method: 16 point BET surface measurement 0.05 to 0.20 p/p0 absolute pressure tolerance: 5.0 mm Hg relative pressure tolerance: 5.0%
evacuation rate: 50.0 mm Hg/second evacuation threshold: 10.0 mm Hg evacuation time: 0.1 h 1 o free space: lower Dewar, t: 0.5 h retention time: 20 seconds minimum equilibration delay: 600 seconds adsorptive: nitrogen C) Determining the droplet size by laser diffraction (according to Mie):
Measuring device: Laser diffraction spectrometer (HELOS), Messrs. Sympatec Software: WINDOX 4 Focal length: 100 mm [measuring range: 0.9.....175 Nm]
2o Measuring method: The droplet size is determined by removing the nozzle from the spray dryer and placing the spray in the upper third of the spray cone in the centre of the laser beam.
Measuring is done at ambient temperature with water as reference medium under otherwise identical conditions.
- 15 - Case 1 /1547 foreign filing text 2) Examples of spray parameters Exa J~le: Spray parameters suitable for an alcoholic solution of (A) (NIRO
Spray dryer SD Micro):
Concentration solution 0.5 g (A) in 100 mL ethanol Droplet size X5o 11 Nm (Reference solution: Hz0 at ambient tem erature Flow volume "spray rate" 4.5 mL / min Spray pressure 0.7 bar overpressure (N2) (nozzle type) (Niro spray nozzle 0.5 mm, Art.-Nr. 248709/A) Flow volume "Atomising pressure"2.2 kg / h (nozzle type) (Niro spray nozzle 0.5 mm, Art.-Nr. 248709/A) entry temperature 149C
exit temperature 96C
Flow volume of "drying gas" 20.1 kg / h cross section of drying tower200 mm 3) Characterisation of the solid particles obtained in the above Example:
~ o Example:
Particle size X5o ~ 1.2 ~m Q~s.s> ~ 99.5%
Specific surface area Sm 21.5 mz/g - 16 - Case 1 /1547 foreign filing text Brief description of the Figures Figures 1 and 2 show photographs of microparticles of the active substance base (A), prepared from an alcoholic spray solution by the process according to the invention.
Claims (15)
1. Powder inhalant, comprising the active substance base 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine or one of the physiologically acceptable salts thereof, in the form of crinkled microparticles, characterised in that (a) they have a specific surface area between 3 m2/g and 35 m2/g, preferably between 5 m2/g and 30 m2/g, particularly preferably between 10 m2/g and 30 m2/g, (b) the characteristic Q(5.8) is between 50% and 100% and (c) the parameter X50 is in the range from 0.5 µm to 10 µm, preferably from 0.5 µm to 10 µm.
2. Powder inhalant according to claim 1, characterised in that the active substance is the free base 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A).
3. Powder inhalant according to claim 1, characterised in that the active substance is selected from the group consisting of 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-
4-(4-pyridinyl)-piperazine hydrochloride, sulphate, phosphate, hydrobromide, carbonate, methanesulphonate, p-toluenesulphonate, nitrate, citrate, malate, tartrate, lactate, succinate, gluconate, acetate, formate, propionate, capronate, oxalate, maleate, fumarate, mandelate and hydroxysuccinate.
4. Powder inhalant according to claim 1, characterised in that the active substance is selected from the group consisting of 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyri-dinyl)-piperazine hydrochloride, sulphate and hydrobromide.
4. Powder inhalant according to claim 1, characterised in that the active substance is selected from the group consisting of 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyri-dinyl)-piperazine hydrochloride, sulphate and hydrobromide.
5. Powder inhalant according to claim 1, characterised in that the active substance is 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine hydrochloride.
6. Powder inhalant according to one of claims 1 to 5, characterised in that it is administered together with one or more physiologically acceptable carrier materials and/or flow adjuvants.
7. Powder inhalant according to claim 6, characterised in that the carrier materials used are monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, polylactides, polyglycolides or mixtures of these carrier materials.
8. Powder inhalant according to claim 6, characterised in that the carrier materials used are glucose, arabinose, lactose or saccharose, maltose, trehalose, dextrans, starch, cellulose derivatives, mannitol, sorbitol, xylitol, sodium chloride, calcium carbonate, polylactides, polyglycolides or mixtures of these carrier materials.
9. Inhalable powder according to claim 6, characterised in that the flow adjuvants used are magnesium stearate, calcium stearate, stearic acid, stearylalcohols, calcium behenate, calcium arachinate, hydrogenated vegetable oils, fatty acid esters, sodium stearyl fumarate, sodium dodecyl sulphate, magnesium dodecyl sulphate or mixtures of these flow adjuvants.
10. Process for preparing the crinkled microparticles of the active substance base (A) according to claim 1, comprising the following steps:
(a) dissolving the active substance (A) in an organic solvent or an organic-aqueous solvent mixture to prepare a sprayable solution with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.%
and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way, so as to obtain a spray mist with a droplet size having the characteristic X50 from 1 to 50 µm, preferably from 1 µm to 30 µm, particularly preferably from 1 µm to 20 µm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C
and (ii) an exit temperature of the drying gas from 40°C to 120°C
and (d) separating the dried solid fraction from the current of drying gas in the usual way.
(a) dissolving the active substance (A) in an organic solvent or an organic-aqueous solvent mixture to prepare a sprayable solution with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.%
and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way, so as to obtain a spray mist with a droplet size having the characteristic X50 from 1 to 50 µm, preferably from 1 µm to 30 µm, particularly preferably from 1 µm to 20 µm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C
and (ii) an exit temperature of the drying gas from 40°C to 120°C
and (d) separating the dried solid fraction from the current of drying gas in the usual way.
11. Process for preparing the crinkled microparticles of the active substance base (A) according to claim 1, comprising the following steps:
(a) dissolving the active substance (A) in an organic solvent or an organic aqueous solvent mixture in order to prepare a sprayable solution with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt. %, (b) spraying the active substance solution thus obtained in the usual way with a flow volume of spray gas of from 1 Nm3/h to 15 Nm3/h, so as to obtain a spray mist with a droplet size having the characteristic X50 from 1 to 50 µm, preferably from 1 µm to 30 µm, particularly preferably from 1 µm to 20 µm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C, (ii) an exit temperature of the drying gas from 40°C to 120°C
and (iii) a flow volume of the drying gas from 15 Nm3/h to 150 Nm3/h and (d) separating the dried solid fraction from the current of drying gas in the usual way.
(a) dissolving the active substance (A) in an organic solvent or an organic aqueous solvent mixture in order to prepare a sprayable solution with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt. %, (b) spraying the active substance solution thus obtained in the usual way with a flow volume of spray gas of from 1 Nm3/h to 15 Nm3/h, so as to obtain a spray mist with a droplet size having the characteristic X50 from 1 to 50 µm, preferably from 1 µm to 30 µm, particularly preferably from 1 µm to 20 µm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C, (ii) an exit temperature of the drying gas from 40°C to 120°C
and (iii) a flow volume of the drying gas from 15 Nm3/h to 150 Nm3/h and (d) separating the dried solid fraction from the current of drying gas in the usual way.
12. Process for preparing the crinkled microparticles of the salts of the active substance base (A) according to claim 1, comprising the following steps:
(a) dissolving the active substance base (A) in water or an aqueous buffer system and adding the corresponding acid in order to prepare a sprayable salt solution of the active substance with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way, so as to obtain a spray mist with a droplet size having the characteristic X50 from 1 to 50 µm, preferably from 1 µm to 30 µm, particularly preferably from 1 µm to 20 µm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C
and (ii) an exit temperature of the drying gas from 40°C to 120°C
and (d) separating the dried solid fraction from the current of drying gas in the usual way.
(a) dissolving the active substance base (A) in water or an aqueous buffer system and adding the corresponding acid in order to prepare a sprayable salt solution of the active substance with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way, so as to obtain a spray mist with a droplet size having the characteristic X50 from 1 to 50 µm, preferably from 1 µm to 30 µm, particularly preferably from 1 µm to 20 µm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C
and (ii) an exit temperature of the drying gas from 40°C to 120°C
and (d) separating the dried solid fraction from the current of drying gas in the usual way.
13. Process for preparing the crinkled microparticles of the salts of the active substance base (A) according to claim 1, comprising the following steps:
(a) dissolving the active substance base (A) in water or an aqueous buffer system and adding the corresponding acid in order to prepare a sprayable salt solution of the active substance with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way with a flow volume of spray gas of from 1 Nm3/h to 15 Nm3/h, so as to obtain a spray mist with a droplet size having the characteristic X50 from 1 to 50 µm, preferably from 1 µm to 30 µm, particularly preferably from 1 µm to 20 µm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C, (ii) an exit temperature of the drying gas from 40°C to 120°C
and (iii) a flow volume of the drying gas from 15 Nm3/h to 150 Nm3/h and (d) separating the dried solid fraction from the current of drying gas in the usual way.
(a) dissolving the active substance base (A) in water or an aqueous buffer system and adding the corresponding acid in order to prepare a sprayable salt solution of the active substance with a concentration of active substance of between 0.2 and 4 wt.%, preferably between 0.2 wt.% and 3 wt.%, particularly preferably between 0.3 wt.% and 2 wt.%, (b) spraying the active substance solution thus obtained in the usual way with a flow volume of spray gas of from 1 Nm3/h to 15 Nm3/h, so as to obtain a spray mist with a droplet size having the characteristic X50 from 1 to 50 µm, preferably from 1 µm to 30 µm, particularly preferably from 1 µm to 20 µm, (c) drying the spray mist thus obtained using a drying gas while applying the following parameters:
(i) an entry temperature of the drying gas from 100°C to 350°C, preferably from 120°C to 250°C and particularly preferably from 130°C to 200°C, (ii) an exit temperature of the drying gas from 40°C to 120°C
and (iii) a flow volume of the drying gas from 15 Nm3/h to 150 Nm3/h and (d) separating the dried solid fraction from the current of drying gas in the usual way.
14. Use of the crinkled microparticles prepared according to claims 10 to 13 for preparing a powder inhalant according to claim 1.
15. Microparticles, obtainable by a process as described in claims 10 to 13.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEDE10338402.2 | 2003-08-18 | ||
| DE2003138402 DE10338402A1 (en) | 2003-08-18 | 2003-08-18 | Spray-dried, amorphous BIBN 4096, process for its preparation and its use as inhalant |
| PCT/EP2004/009012 WO2005018603A2 (en) | 2003-08-18 | 2004-08-12 | Spray-dried amorphous bibn 4096 method for production and use thereof as inhalant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2536047A1 true CA2536047A1 (en) | 2005-03-03 |
Family
ID=34201781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002536047A Abandoned CA2536047A1 (en) | 2003-08-18 | 2004-08-12 | Spray-dried amorphous bibn 4096 method for production and use thereof as inhalant |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1663149A2 (en) |
| JP (1) | JP2007502789A (en) |
| CA (1) | CA2536047A1 (en) |
| DE (1) | DE10338402A1 (en) |
| WO (1) | WO2005018603A2 (en) |
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9339615B2 (en) | 2008-06-13 | 2016-05-17 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
| US9346766B2 (en) | 2004-08-20 | 2016-05-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
| US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
| US9446001B2 (en) | 2005-09-14 | 2016-09-20 | Mannkind Corporation | Increasing drug affinity for crystalline microparticle surfaces |
| US9610351B2 (en) | 2011-10-24 | 2017-04-04 | Mannkind Corporation | Methods and compositions for treating pain |
| US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| US9655850B2 (en) | 2008-12-29 | 2017-05-23 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
| US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
| US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
| US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
| US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
| US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
| US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| US10130581B2 (en) | 2006-02-22 | 2018-11-20 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
| US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
| US10675421B2 (en) | 2008-06-20 | 2020-06-09 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
| US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10338407A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New inhalable powders containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine |
| DE10338399A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Microparticles containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine, process for their preparation and their use as inhalation powder |
| JP6267685B2 (en) | 2012-04-13 | 2018-01-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Aggregated particles |
| ME03483B (en) * | 2013-06-19 | 2020-01-20 | Aicuris Anti Infective Cures Gmbh | Amorphous letermovir and solid pharmaceutical formulations thereof for oral administrationletermovir |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1242211A (en) * | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
| AU2001230533A1 (en) * | 2000-02-04 | 2001-08-14 | Kissei Pharmaceutical Co. Ltd. | Powdered preparation for inhalation and powder inhalant containing the same packed |
| GB0014851D0 (en) * | 2000-06-16 | 2000-08-09 | Glaxo Group Ltd | Novel pharmaceutical formulation |
| DE10139410A1 (en) * | 2001-08-17 | 2003-02-27 | Boehringer Ingelheim Pharma | Use of BIBN4096 in combination with other anti-migraine drugs for the treatment of migraines |
| DE10206770A1 (en) * | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | New, stable acid addition salts of the quinazolinone derivative CGRP antagonist BIBN4096, useful for the treatment of migraine, in the form of an inhalable powder |
| DE10207026A1 (en) * | 2002-02-20 | 2003-08-28 | Boehringer Ingelheim Kg | Stable inhalable powder of the calcitonin gene-related peptide antagonist, BIBN4096, useful for treating migraine, in the form of spherical nano-structured particles obtained by spray-drying |
| DE10338399A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Microparticles containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine, process for their preparation and their use as inhalation powder |
| DE10338407A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New inhalable powders containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine |
| DE10338403A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant |
-
2003
- 2003-08-18 DE DE2003138402 patent/DE10338402A1/en not_active Withdrawn
-
2004
- 2004-08-12 CA CA002536047A patent/CA2536047A1/en not_active Abandoned
- 2004-08-12 WO PCT/EP2004/009012 patent/WO2005018603A2/en active Application Filing
- 2004-08-12 JP JP2006523576A patent/JP2007502789A/en active Pending
- 2004-08-12 EP EP04764016A patent/EP1663149A2/en not_active Withdrawn
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9801925B2 (en) | 1999-06-29 | 2017-10-31 | Mannkind Corporation | Potentiation of glucose elimination |
| US9700690B2 (en) | 2002-03-20 | 2017-07-11 | Mannkind Corporation | Inhalation apparatus |
| US9346766B2 (en) | 2004-08-20 | 2016-05-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
| US9796688B2 (en) | 2004-08-20 | 2017-10-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
| US9675674B2 (en) | 2004-08-23 | 2017-06-13 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
| US10130685B2 (en) | 2004-08-23 | 2018-11-20 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
| US9446001B2 (en) | 2005-09-14 | 2016-09-20 | Mannkind Corporation | Increasing drug affinity for crystalline microparticle surfaces |
| US9717689B2 (en) | 2005-09-14 | 2017-08-01 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| US10143655B2 (en) | 2005-09-14 | 2018-12-04 | Mannkind Corporation | Method of drug formulation |
| US10130581B2 (en) | 2006-02-22 | 2018-11-20 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| US9446133B2 (en) | 2008-06-13 | 2016-09-20 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
| US9662461B2 (en) | 2008-06-13 | 2017-05-30 | Mannkind Corporation | Dry powder drug delivery system and methods |
| US10201672B2 (en) | 2008-06-13 | 2019-02-12 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
| US10342938B2 (en) | 2008-06-13 | 2019-07-09 | Mannkind Corporation | Dry powder drug delivery system |
| US9511198B2 (en) | 2008-06-13 | 2016-12-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
| US9339615B2 (en) | 2008-06-13 | 2016-05-17 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
| US10751488B2 (en) | 2008-06-13 | 2020-08-25 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
| US10675421B2 (en) | 2008-06-20 | 2020-06-09 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
| US9943571B2 (en) | 2008-08-11 | 2018-04-17 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10172850B2 (en) | 2008-12-29 | 2019-01-08 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US9655850B2 (en) | 2008-12-29 | 2017-05-23 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US9983108B2 (en) | 2009-03-11 | 2018-05-29 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| US9630930B2 (en) | 2009-06-12 | 2017-04-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| US9706944B2 (en) | 2009-11-03 | 2017-07-18 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
| US10625034B2 (en) | 2011-04-01 | 2020-04-21 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
| US9364436B2 (en) | 2011-06-17 | 2016-06-14 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
| US10130709B2 (en) | 2011-06-17 | 2018-11-20 | Mannkind Corporation | High capacity diketopiperazine microparticles and methods |
| US10258664B2 (en) | 2011-10-24 | 2019-04-16 | Mannkind Corporation | Methods and compositions for treating pain |
| US9610351B2 (en) | 2011-10-24 | 2017-04-04 | Mannkind Corporation | Methods and compositions for treating pain |
| US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
| US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
| US10421729B2 (en) | 2013-03-15 | 2019-09-24 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005018603A2 (en) | 2005-03-03 |
| JP2007502789A (en) | 2007-02-15 |
| WO2005018603A3 (en) | 2005-07-21 |
| DE10338402A1 (en) | 2005-03-17 |
| EP1663149A2 (en) | 2006-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2536047A1 (en) | Spray-dried amorphous bibn 4096 method for production and use thereof as inhalant | |
| US20050043247A1 (en) | Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative | |
| JP2007502789A6 (en) | Spray-dried amorphous BIBN4096, its preparation method and its use as an inhalant | |
| US20050147568A1 (en) | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them | |
| US11872314B2 (en) | Pharmaceutical compositions | |
| JP4085064B2 (en) | Method for preparing an inhalable powder containing a salt of CGRP antagonist BIBN4096 | |
| US20080038357A1 (en) | Inhalation Powder Containing the CGRP antagonist BIBN4096 and Process for the Preparation Thereof | |
| JP2007502789A5 (en) | ||
| CN104274426A (en) | Novel aerosol formulations of ondansetron and uses thereof | |
| US20050042178A1 (en) | Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder | |
| JP4085063B2 (en) | Inhalable powder containing CGRP antagonist BIBN4096 and method for preparing the same | |
| JP2007502790A (en) | CGRP antagonist 1- [N2- [3,5-dibromo-N-[[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl ] -L-lysyl] -4- (4-pyridinyl) -piperazine-containing microparticles, process for their preparation and their use as inhalation powder | |
| JP2007502790A6 (en) | CGRP antagonist 1- [N2- [3,5-dibromo-N-[[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl ] -L-lysyl] -4- (4-pyridinyl) -piperazine-containing microparticles, process for their preparation and their use as inhalation powder | |
| CA2536053A1 (en) | Powder formulation comprising the cgrp antagonist 1-(n2-(3,5-dibromo-n-(4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)- 1-piperidinyl)carbonyl)-d-tyrosyl)-l-lysyl)-4-(4-pyridinyl)-piperazine | |
| CA2536050A1 (en) | Novel inhalation powder comprising the cgrp antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine | |
| US20050042180A1 (en) | Powder formulation containing the CGRP antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder | |
| JP2007502792A6 (en) | CGRP antagonist 1- [N2- [3,5-dibromo-N-[[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl ] -L-lysyl] -4- (4-pyridinyl) -piperazine-containing powder preparation, its production method and use as inhaled powder | |
| RU2818086C2 (en) | Intranasal pharmaceutical powder compositions | |
| JP2007502790A5 (en) | ||
| US20060222599A1 (en) | Inhalative powder formulations containing the CGRP-antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine | |
| KR20180052566A (en) | Tripentad powder for pulmonary delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |